Hammersmith Medicines Research
London, United Kingdom
NCT Number: NCT04941781
This is a Phase 1, single-center, open-label, adaptive-design PET study to investigate the occupancy of brain muscarinic Type 1 receptors (M1AChR) by PIPE-307 in healthy volunteers.
Looking for future studies?
Notify Me25 year–65 year
All sexes
Interventional
Phase 1
London, United Kingdom
This is a Phase 1, single-center, open-label, adaptive-design study to investigate the occupancy of brain M1AChR after a single oral dose of PIPE-307 in healthy volunteers by positron emission tomography (PET) using the radioligand [11C] PIPE-307.
This study will have an adaptive design to adequately evaluate the relationship between PIPE-307 exposure and brain M1AChR occupancy.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Criteria:
Key Exclusion Criteria:
Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with [11C] PIPE-307.
Subjects will receive an intravenous dose of the radioligand [11C] PIPE-307 prior to PET imaging.
Time frame: 24 hours
Contineum Therapeutics
Industry
A Phase 1, Open-label Study of PIPE-307 to Determine Muscarinic Type I Receptor (M1AChR) Occupancy Parameters by [11C] PIPE-307 PET Imaging in Healthy Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsNCT02511028
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bethesda, Maryland, United States
View Trial DetailsNCT07175792
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Diepenbeek, Belgium
View Trial DetailsNCT07726667
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Gaziantep, Gaz, Turkey (Türkiye)
View Trial Details